{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:20:18Z","timestamp":1790911218374,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.clml.2017.06.028","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:46:47Z","timestamp":1498279607000},"page":"569-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Smith","family":"Giri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Gregory","family":"Bociek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.028_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib2","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib4","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib5","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.06.028_bib7","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib8","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.028_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.028_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ajh.23708","article-title":"The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras","volume":"89","author":"Nabhan","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.06.028_bib11","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study","volume":"93","author":"Sacchi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.028_bib13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/bjc.2013.381","article-title":"Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study","volume":"109","author":"Beiggi","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2017.06.028_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B","volume":"21","author":"Peterson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib15","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12185-014-1629-4","article-title":"Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group","volume":"100","author":"Hirayama","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2017.06.028_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.028_bib18","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2017.06.028_bib19","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.clml.2016.02.016","article-title":"A\u00a0concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms","volume":"16","author":"Mascarenhas","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.06.028_bib20","first-page":"4051","article-title":"Effect of adjuvant radiotherapy on survival in patients with locoregional urothelial malignancies of the upper urinary tract","volume":"36","author":"Hahn","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2017.06.028_bib21","volume":"Vol. 360","author":"Kalbfleisch","year":"2011"},{"key":"10.1016\/j.clml.2017.06.028_bib22","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib23","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2017.06.028_bib24","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3109\/10428194.2015.1007505","article-title":"Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma","volume":"56","author":"Rossi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.028_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(05)70387-9","article-title":"Lung cancer after treatment for Hodgkin's lymphoma: a systematic review","volume":"6","author":"Lorigan","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib26","first-page":"453","article-title":"Etiology and management of therapy-related myeloid leukemia","volume":"2007","author":"Larson","year":"2007","journal-title":"ASH Education Book"},{"key":"10.1016\/j.clml.2017.06.028_bib27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.028_bib28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","article-title":"Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study","volume":"24","author":"Mudie","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.06.028_bib30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.hoc.2014.08.015","article-title":"Hematopoietic stem cell transplantation for non-Hodgkin lymphoma","volume":"28","author":"Bhatt","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2017.06.028_bib31","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-014-2288-5","article-title":"Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab","volume":"94","author":"Berinstein","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.06.028_bib33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4161\/cbt.26342","article-title":"Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients","volume":"14","author":"Akhtari","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clml.2017.06.028_bib35","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/10428190500144656","article-title":"Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: long-term autologous transplantation experience in follicular and mantle cell lymphoma","volume":"46","author":"Fenske","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.028_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.028_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/hon.2015","article-title":"Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis","volume":"31","author":"Wang","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib38","first-page":"CD007678","article-title":"High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults","volume":"1","author":"Schaaf","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2017.06.028_bib39","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.028_bib41","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1182\/blood.V120.21.4876.4876","article-title":"The risk of secondary myelodysplastic syndrome\/acute leukemia and second malignancy following yttrium-90 ibritumomab tiuxetan: 10-year single-institution experience of 138 consecutive patients","volume":"120","author":"Vanazzi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.028_bib42","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90 Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017301714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017301714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:28Z","timestamp":1761870568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017301714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S2152265017301714"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.028","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}